Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Mayo Clinic researchers have identified a subset of BRCA2 gene variants — called hypomorphic variants — that only partially disrupt gene function and carry a much lower lifetime breast cancer risk (20–25%) compared to the 50–70% risk of typical harmful BRCA2 mutations. The discovery could reshape how clinicians personalize screening and prevention strategies, including decisions around risk-reducing surgery and PARP inhibitor therapy.
Not every BRCA2 mutation is a red alert. Mayo Clinic researchers have identified 70 BRCA2 "hypomorphic" variants — gene changes that only partially disrupt BRCA2 function — and found they carry a meaningfully lower lifetime breast cancer risk than the mutations clinicians typically flag. Published in Nature Communications, the study draws on large-scale hereditary cancer testing data to characterize this distinct, moderate-risk category.
Carriers of these hypomorphic variants face an estimated 20–25% lifetime risk of breast cancer, compared to the 50–70% risk associated with standard high-penetrance BRCA2 mutations. That difference matters enormously when patients and their care teams are weighing options like risk-reducing mastectomy or oophorectomy — surgeries that may be unnecessary for this group.
Key Takeaways:
Why it matters: Precision in genetic risk assessment directly shapes life-altering clinical decisions. By distinguishing moderate-risk variants from high-risk ones, this research paves the way for more tailored — and less aggressive — cancer prevention strategies for a meaningful subset of BRCA2 carriers.